Abstract
Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are widely used in renal failure patients in the treatment of hypertension [1], left ventricular dysfunction [2], and diabetic nephropathy [3]. Their efficacy in these conditions is well established, and generally both classes of drugs are well tolerated, with a low incidence of side effects [4]. Thus, ACE inhibitors may induce skin rashes, angioneurotic oedema, diarrhoea, cough, and dizziness [5], while the angiotensin II blockers have a side effect profile not dissimilar to placebo.

This publication has 21 references indexed in Scilit: